SCHM Shares Cross Below 200 DMA
52 Week Range of SCHM: SCHM's stock has a 52-week low of $62.87 and a high of $82.28, with the last trade recorded at $77.06.
Market Analysis: The article suggests checking other ETFs that have recently fallen below their 200-day moving average.
Trade with 70% Backtested Accuracy
Analyst Views on SCHM
About the author
Significant ETF Withdrawals: SCHM, SNDK, TPR, STLD
52-Week Range Analysis: SCHM's share price has a 52-week low of $22.41 and a high of $30.3051, with the last trade recorded at $29.54.
Understanding ETFs: Exchange traded funds (ETFs) function like stocks, where investors buy and sell "units" that can be created or destroyed based on demand.
Monitoring ETF Flows: Weekly monitoring of shares outstanding helps identify ETFs with significant inflows (new units created) or outflows (old units destroyed), impacting the underlying holdings.
Disclaimer: The views expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.
Unexpected Analyst 12-Month Forecast for SCHM
ETF Analysis: The Schwab U.S. Mid-Cap ETF (SCHM) has an implied analyst target price of $33.94, indicating a potential upside of 14.77% from its current trading price of $29.57.
Notable Holdings: Key underlying holdings with significant upside potential include Glaukos Corp (53.33% upside), Darling Ingredients Inc (45.94% upside), and CCC Intelligent Solutions Holdings Inc (37.81% upside) based on their respective analyst target prices.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets may lead to downgrades if they do not align with recent developments.
Investor Research: Investors are encouraged to conduct further research to assess the validity of analyst targets and their implications for future stock performance.
Examine the Details: SCHM Offers a 12% Potential Gain
ETF Analysis: The Schwab U.S. Mid-Cap ETF (SCHM) has an implied analyst target price of $33.58, indicating a potential upside of 12.13% from its current trading price of $29.95.
Notable Holdings: Key underlying holdings with significant upside potential include Acadia Healthcare (36.79% upside), Clarivate (27.18% upside), and Valvoline (12.39% upside) based on their respective analyst target prices.
Putting It All Together: SCHM May Have a Value of $33
ETF Analysis: The Schwab U.S. Mid-Cap ETF (SCHM) has an implied analyst target price of $33.11 per unit, indicating a potential upside of 12% from its current trading price of $29.56.
Notable Holdings: Key underlying holdings contributing to this upside include Noble Corporation plc (NE), RenaissanceRe Holdings Ltd. (RNR), and SouthState Corp (SSB), each showing significant potential for price increases based on analyst targets.
Analyst Target Comparisons: NE is expected to rise by 18.01% to a target of $33.86/share, RNR by 13.57% to $277.50/share, and SSB by 13.01% to $115.00/share, compared to their recent prices.
Investor Considerations: Questions arise regarding the validity of these analyst targets, suggesting that investors should conduct further research to determine if the optimism reflected in these targets is justified or overly optimistic.
The Implied Analyst 12-Month Target For SCHM
ETF Analysis: The Schwab U.S. Mid-Cap ETF (SCHM) has an implied analyst target price of $32.87, indicating a potential upside of 12.30% from its current trading price of $29.27. Notable underlying holdings with significant upside include SPS Commerce, Morningstar Inc., and UiPath Inc.
Investor Considerations: Analysts' target prices may reflect optimism or could be outdated, prompting further research by investors to determine the validity of these projections in light of recent company and industry developments.
How The Parts Add Up: SCHM Headed For $32
ETF Analysis: The Schwab U.S. Mid-Cap ETF (SCHM) has an implied analyst target price of $31.68, indicating a potential upside of 9.73% from its current trading price of $28.87.
Individual Holdings Performance: Notable underlying holdings such as CNA Financial Corp, CubeSmart, and e.l.f. Beauty Inc show significant upside potential based on analysts' target prices, raising questions about the validity of these targets in light of recent market developments.
Significant ETF Withdrawals: SCHM, SNDK, TPR, STLD
52-Week Range Analysis: SCHM's share price has a 52-week low of $22.41 and a high of $30.3051, with the last trade recorded at $29.54.
Understanding ETFs: Exchange traded funds (ETFs) function like stocks, where investors buy and sell "units" that can be created or destroyed based on demand.
Monitoring ETF Flows: Weekly monitoring of shares outstanding helps identify ETFs with significant inflows (new units created) or outflows (old units destroyed), impacting the underlying holdings.
Disclaimer: The views expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.
Unexpected Analyst 12-Month Forecast for SCHM
ETF Analysis: The Schwab U.S. Mid-Cap ETF (SCHM) has an implied analyst target price of $33.94, indicating a potential upside of 14.77% from its current trading price of $29.57.
Notable Holdings: Key underlying holdings with significant upside potential include Glaukos Corp (53.33% upside), Darling Ingredients Inc (45.94% upside), and CCC Intelligent Solutions Holdings Inc (37.81% upside) based on their respective analyst target prices.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets may lead to downgrades if they do not align with recent developments.
Investor Research: Investors are encouraged to conduct further research to assess the validity of analyst targets and their implications for future stock performance.
Examine the Details: SCHM Offers a 12% Potential Gain
ETF Analysis: The Schwab U.S. Mid-Cap ETF (SCHM) has an implied analyst target price of $33.58, indicating a potential upside of 12.13% from its current trading price of $29.95.
Notable Holdings: Key underlying holdings with significant upside potential include Acadia Healthcare (36.79% upside), Clarivate (27.18% upside), and Valvoline (12.39% upside) based on their respective analyst target prices.
Putting It All Together: SCHM May Have a Value of $33
ETF Analysis: The Schwab U.S. Mid-Cap ETF (SCHM) has an implied analyst target price of $33.11 per unit, indicating a potential upside of 12% from its current trading price of $29.56.
Notable Holdings: Key underlying holdings contributing to this upside include Noble Corporation plc (NE), RenaissanceRe Holdings Ltd. (RNR), and SouthState Corp (SSB), each showing significant potential for price increases based on analyst targets.
Analyst Target Comparisons: NE is expected to rise by 18.01% to a target of $33.86/share, RNR by 13.57% to $277.50/share, and SSB by 13.01% to $115.00/share, compared to their recent prices.
Investor Considerations: Questions arise regarding the validity of these analyst targets, suggesting that investors should conduct further research to determine if the optimism reflected in these targets is justified or overly optimistic.
The Implied Analyst 12-Month Target For SCHM
ETF Analysis: The Schwab U.S. Mid-Cap ETF (SCHM) has an implied analyst target price of $32.87, indicating a potential upside of 12.30% from its current trading price of $29.27. Notable underlying holdings with significant upside include SPS Commerce, Morningstar Inc., and UiPath Inc.
Investor Considerations: Analysts' target prices may reflect optimism or could be outdated, prompting further research by investors to determine the validity of these projections in light of recent company and industry developments.
How The Parts Add Up: SCHM Headed For $32
ETF Analysis: The Schwab U.S. Mid-Cap ETF (SCHM) has an implied analyst target price of $31.68, indicating a potential upside of 9.73% from its current trading price of $28.87.
Individual Holdings Performance: Notable underlying holdings such as CNA Financial Corp, CubeSmart, and e.l.f. Beauty Inc show significant upside potential based on analysts' target prices, raising questions about the validity of these targets in light of recent market developments.
